Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The clinical effectiveness of opioid maintenance for heroin dependence is believed to result from a medication's ability to decrease mu-opioid receptor (muOR) availability thereby replacing agonist effects, alleviating withdrawal symptoms and attenuating heroin effects. We empirically tested this hypothesis in five heroin-dependent volunteers who were successively maintained on 32, 16, 2, and 0 mg daily buprenorphine (BUP) tablet doses. We predicted and confirmed that higher BUP doses would decrease in vivo muOR availability (measured with PET and [(11)C]carfentanil), increase plasma levels of BUP and its metabolite nor-BUP, and decrease withdrawal symptoms and hydromorphone (HYD) responses. Relative to placebo, BUP significantly decreased mean (+/-SEM) whole-brain muOR availability 41+/-8, 80+/-2, and 84+/-2% at 2, 16, and 32 mg, respectively. Regions of interest (ROIs) (prefrontal cortex, anterior cingulate, thalamus, amygdala, nucleus accumbens, caudate) showed similar dose-dependent effects. Changes in muOR availability varied across ROIs (prefrontal cortex, 47% vs amygdala, 27%) at BUP 2 mg, but were more homogeneous across ROIs at BUP 32 mg (94-98%; except thalamus, 88%). Relative to placebo (0 ng/ml), peak plasma levels of BUP and nor-BUP were comparable and dose-dependent (0.5-1, 5-6, and 13-14 ng/ml at 2, 16, and 32 mg, respectively). muOR availability decreases were negatively correlated with BUP plasma level and positively correlated with questionnaire-based opioid withdrawal symptoms and attenuation of HYD symptoms. These findings suggest that high-dose BUP maintenance produces near-maximal muOR occupation, muOR availability correlates well with plasma levels, and BUP-related opioid symptoms and antagonist blockade exhibit concentration-effect relationships.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“We derived a curve of best fit for buprenorphine from dose-occupancy data in Greenwald et al. 17 (as reported in Greenwald et al. 18 ) where occupancy was measured 4 h after 12 days of maintenance treatment with doses ranging from 1 to 32 mg (Figure 2 and Table 3).”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“This was corroborated by Greenwald et al. (117) who found that higher buprenorphine doses (up to 32 mg given as a tablet*) led to increased plasma buprenorphine levels, decreased μ-opioid receptor availability, and decreased withdrawal symptoms.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
In the citing paper
“In the same study, heroin craving was found to be significantly correlated with μ-opioid receptor availability and negatively correlated with buprenorphine plasma levels.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
McLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“An experienced clinician administered a semistructured interview (SCID-IV; First et al, 1996), and opioid dependence severity was determined using the Addiction Severity Index (McLellan et al, 1985a, b).”
MethodMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Earlier human laboratory studies showed that administration of subcutaneous BUP (Jasinski et al, 1978; Mello et al, 1982) or sublingual BUP liquid (Bickel et al, 1988; Rosen et al, 1994; Walsh et al, 1995) could attenuate the reinforcing, subjective, and physiological effects of mOR agonists.”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethodAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Meyer, C. R., Boes, J. L., Kim, B., Bland, P. H., Zasadny, K. R., Kison, P. V., Koral, K., Frey, K. A., & Wahl, R. L. (1997) · Medical Image Analysis · doi:10.1016/s1361-8415(97)85010-4 · Cited by 460
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethod
Research works printed but not linked: 2
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis Disorders—Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York.
- Lewis JW, Rance MJ, Sanger DJ (1983). The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK (ed). Advances in Substance Abuse Vol. 3 JAI Press: Greenwich, 103–154.
Cited by
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Hedonic Hot Spots in the Brain
Peciña, S., Smith, K. S., & Berridge, K. C. (2006) · The Neuroscientist · doi:10.1177/1073858406293154 · Cited by 441
Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391
Buprenorphine: Clinical Pharmacokinetics in the Treatment of Opioid Dependence
Elkader, A., & Sproule, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544070-00001 · Cited by 335
Metadata
- Authors
- Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K.
- Affiliations
- Wayne State University (US)
- University of Utah (US)
- University of Michigan (US)
- Corresponding author
- Greenwald, Mark K
- Venue
- Neuropsychopharmacology
- Published
- 2003-05-30
- Volume
- 28
- Issue
- 11
- Pages
- 2000-2009
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2040327352
- Cited by
- 320
- References
- 44
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 23 · 2020: 20 · 2019: 20 · 2018: 11 · 2017: 14 · 2016: 3 · 2015: 12 · 2014: 11 · 2013: 22 · 2012: 14
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wayne State University
- U.S. Public Health Service (DA00254)
- National Institute on Drug Abuse (R01 DA 10100, P50DA000254, DA-00254, R01DA010100, P50 DA00254, P01DA000254)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- buprenorphine, heroin addiction, opioid maintenance treatment, dose-response relationship, opioid withdrawal symptoms
- MeSH terms
- Adult, Analysis of Variance, Buprenorphine, Dose-Response Relationship, Drug, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotic Antagonists, Tomography, Emission-Computed, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers. https://app.cochat.ai/papers/10.1038/sj.npp.1300251
- The paper
- Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003). Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1300251
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.